On Wednesday, May 13, ResMed released a field study notice that likely affects many patients currently being treated for central sleep apnea syndrome with adaptive servo-ventilation (ASV). The early results of a randomized controlled SERVE-HF study indicate that there is an increased risk of cardiovascular death with ASV treatment for patients with central sleep apnea syndrome; symptomatic, chronic heart failure; and a reduced left ventricular ejection fraction.
A short presentation and discussion of ASV Therapy for the CSA Patient with Heart Failure is scheduled immediately following the AAST General Membership meeting on Monday, June 8, 2015 at 5:30 PM in the Grand Ballroom at the Seattle Sheraton.
Dr. Glenn Richards, ResMed Chief Medical Officer, will review the preliminary findings of the study, and discuss appropriate management of this patient population. AAST President, Laura Linley and AAST Immediate Past President, Rita Brooks will facilitate a discussion of this issue following the presentation.